INVESTOR RELATIONS
(OTC PINK: BWVI)
CORPORATE OVERVIEW
Psycheceutical Bioscience Inc. (OTC PINK: BWVI) is a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments. Powered by a team of FDA drug development veterans, leading mental health scientists, and a network of international partners, Psycheceutical is on a mission to develop precision dosing technologies and more effective tools to provide the safe and effective delivery of psychedelic pharmaceutical medicines.
Our next-generation patented delivery technologies, via systemic and non-systemic routes of administration, are expected to allow psychedelics to be administered without unwanted side effects and toxicity, providing direct and profound benefits to those suffering from mental health disorders.
WHY INVEST
2 Patented Drug Delivery Technologies
designed to increase the safety and efficacy of psychedelic therapeutics while eliminating hallucinations and side effects.
2 Active Clinical Research Programs
NeuroDirect™ ketamine topical for PTSD — clinical trials Q2 2023.
Second drug for the treatment of addiction in pre-clinical stage.
An Experienced, Visionary Team
consisting of medical specialists, biotechnology scientists, FDA regulatory advisors, psychedelic industry insiders, and business development experts.
LATEST ANNOUNCEMENTS
Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect Ketamine for PTSD
Company's novel NeuroDirectTM topical ketamine formulation to treat PTSD shown to be safe and well-tolerated in first cohort of Phase I trial.
Read More Psycheceutical Bioscience Announces Completion of PCAOB Audit and Future Corporation Action Strategy
Psycheceutical today announced that its auditors RBSM LLP have completed a PCAOB audit of the company's financial statements for the periods ending December 31, 2022 and 2021.
Read More First Patient Dosed in Psycheceutical’s Phase I Study Exploring Topical Administration of Ketamine to Treat PTSD
Psycheceutical’s clinical trial program is the first ever to test the topical application of ketamine for use in treating a mental health disorder through the company’s NeuroDirect™ delivery system.
Read More EVENTS + MEDIA
Latest Events
- Benzinga Psychedelics Capital Conference
April 13, 2023 | Miami Beach - Annual Cannabis & Psychedelics Investment Summit
February 27, 2023 | Coral Gables, FL
- Cannadelic Conference
February 2-4, 2023 | Miami
- Microdose Wonderland
November 5, 2022 | Miami
